Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon.
Nat Commun. 2021 Oct 6;12(1):5851. doi: 10.1038/s41467-021-25946-0.
Nat Commun. 2021.
PMID: 34615863
Free PMC article.
Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon.
Ndongo FA, Guichet E, Mimbé ED, Ndié J, Pelloquin R, Varloteaux M, Esemu L, Mpoudi-Etame M, Lamare N, Edoul G, Wouambo RK, Djomsi DM, Tongo M, Tabala FN, Dongmo RK, Diallo MSK, Bouillin J, Thaurignac G, Ayouba A, Peeters M, Delaporte E, Bissek AZ, Mpoudi-Ngolé E.
Ndongo FA, et al. Among authors: mimbe ed.
Emerg Infect Dis. 2022 Jun;28(6):1233-1236. doi: 10.3201/eid2806.212580. Epub 2022 Apr 26.
Emerg Infect Dis. 2022.
PMID: 35470795
Free PMC article.
Item in Clipboard
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group.
Bousmah MA, et al.
Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23.
Pharmacoeconomics. 2021.
PMID: 33355914
Free PMC article.
Item in Clipboard
Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
Mpoudi-Etame M, Tovar Sanchez T, Bousmah MA, Omgba Bassega P, Olinga J, Mimbe E, Foalem M, Chiep C, Edimo S, Varloteaux M, Pelloquin R, Lamare N, Boyer S, Peeters M, Reynes J, Calmy A, Hill A, Delaporte E, Kouanfack C; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-income countries (NAMSAL-ANRS-12313) study group.
Mpoudi-Etame M, et al. Among authors: mimbe e.
Open Forum Infect Dis. 2023 Nov 20;10(12):ofad582. doi: 10.1093/ofid/ofad582. eCollection 2023 Dec.
Open Forum Infect Dis. 2023.
PMID: 38156046
Free PMC article.
Item in Clipboard
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A, Tovar Sanchez T, Kouanfack C, Mpoudi-Etame M, Leroy S, Perrineau S, Lantche Wandji M, Tetsa Tata D, Omgba Bassega P, Abong Bwenda T, Varloteaux M, Tongo M, Mpoudi-Ngolé E, Montoyo A, Mercier N, LeMoing V, Peeters M, Reynes J, Delaporte E; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group.
Calmy A, et al.
Lancet HIV. 2020 Oct;7(10):e677-e687. doi: 10.1016/S2352-3018(20)30238-1.
Lancet HIV. 2020.
PMID: 33010241
Clinical Trial.
Item in Clipboard
Cite
Cite